Carboxypeptidase N1 is anticipated to be a synergy metrics for chemotherapy effectiveness and prognostic significance in invasive breast cancer
| Autor: | Tiantian Li, Yueguo Li, Ranliang Cui, Li Ren, Jialei Hua, Ting Zhao, Chaomin Wang, Yichao Wang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.medical_treatment Breast cancer Internal medicine Genetics medicine Chemotherapeutic efficacy Stage (cooking) Risk factor RC254-282 Chemotherapy Tissue microarray QH573-671 Proportional hazards model business.industry Incidence (epidemiology) Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Prognosis Chemotherapy regimen CA153 Carboxypeptidase N1 business Cytology Primary Research Invasive breast cancer |
| Zdroj: | Cancer Cell International Cancer Cell International, Vol 21, Iss 1, Pp 1-12 (2021) |
| ISSN: | 1475-2867 |
| Popis: | Background The incidence and mortality of invasive breast cancer (IBC) are increasing annually. Hence, it is urgently needed to determine reliable biomarkers for not only monitoring curative effects, but evaluating prognosis. In present study, we aim to determine the potential role of Carboxypeptidase N1 (CPN1) in IBC tissues on chemotherapeutic efficacy and poor prognosis. Methods The expression level of CPN1 in IBC tissue samples (n = 123) was quantified by tissue microarray technique and immunohistochemical staining. Moreover, sera of IBC patients (n = 34) that underwent three to five consecutive chemotherapy sessions were collected. The patients were randomly stratified into a training (n = 15) as well as a validation group (n = 19). The expression of serum CA153 and CPN1 was quantified by electrochemiluminescence and ELISA assay, respectively. Results By univariate and multivariate Cox regression analysis, we show that CPN1 expression in IBC tissues, as an independent risk factor, is related to a poor overall survival (OS) and progression-free survival (PFS) (P CPN1 = 0.834 vs. AUCCA153 = 0.724) as well as the validation set (AUCCPN1 = 0.860 vs. AUCCA153 = 0.720) when comparing cycle2 versus cycle3. Conclusions CPN1 is a suitable potential biomarker for chemotherapeutic surveillance purposes as well as being an appropriate prognostic indicator which would support an improved chemotherapy regimen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|